The first long-term comparison of psilocybin vs an SSRI for MDD suggests the psychedelic was associated with better overall ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the ...

This study aimed to explore the association between major depressive disorder (MDD) and suicide risk in dementia patients.A cohort of 625,218 individuals aged ≥40 years with dementia between 2007 and ...

The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in ...

The AMPLIFY trial will assess the safety and efficacy of ABX-002 when used alongside existing SSRI or SNRI treatments.

Pediatric patients are also more susceptible to becoming addicted to ketamine and forming substance abuse disorders.

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an ...

STIM recently announced that additional payors have updated the coverage of TMS (transcranial magnetic stimulation). This upgrade is aimed at reducing the access barriers for patients with major ...

A study comparing psilocybin to the SSRI escitalopram found both drugs improved depressive symptoms similarly over six months ...

Depressive symptoms can manifest in different ways. Often, they can interrupt your sleep quality. Here’s what to do about it.

Here's a look at the best and worst states in each of the four data categories: mental health provider ratio, suicide rate ...